Medical News

Personalized Vaccine Helps Decrease HIV Patients' Viral Load, Study Says

February 3, 2011

"Twenty-four AIDS patients took part in a clinical trial [of a vaccine] carried out by doctors at Barcelona's Hospital Clinic and after 24 weeks the majority had shown a 'significant' decrease in their viral load, the hospital said" on Tuesday, Agence France-Presse/Montreal Gazette reports. "This decrease was very significant is some of them but in no case did the virus become undetectable," the hospital said in a statement. "However this is a very important improvement with respect to previous initiatives where with a similar vaccine there was a modest response in 30 percent of the treated patients. No therapeutic vaccine has achieved up to now the same level of response as in this study," the statement said. Vaccines in the study were personalized and made from the patient's own dendritic cells, which play a key role in regulating the immune system. The results of the study were published in the Journal of Infectious Diseases (2/1).

Back to other news for February 2011

This information was reprinted from with permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives, and sign up for email delivery. © Henry J. Kaiser Family Foundation. All rights reserved.

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.